Abciximab Articles
New York Stock Comment
25 September 1997
New Studies At European Cardiology Meeting
15 September 1997
Out-Of-Favor Drug Shows Promise In Restenosis
4 September 1997
New York Stock Comment
3 September 1997
COR Therapeutics Boosted By Integrilin Data
28 August 1997
Smaller US Firms' Losses Grow Due To R&D Costs
31 July 1997
Centocor To Settle Litigation
12 June 1997
Celltech Refocuses On Lower-Risk Projects
30 May 1997
Fujisawa Sees 31% Net Income Rise For FY1996
26 May 1997
Higher Biotech Earnings But Investors Stay Cool
19 May 1997
Strong Dollar Impact On Eli Lilly
5 May 1997
Dutch Unit Of Centocor Expanding
5 May 1997
Tirofiban Cuts Mortality In Unstable Angina Patients
26 March 1997
Integrilin Fails To Get US Approval Recommendation
10 March 1997
Strong Financials Back Celltech's R&D
10 March 1997
Expanded Use Sought For Centocor's ReoPro
24 February 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
NEW YORK STOCK COMMENT
13 January 1997
Celltech Forecast
9 December 1996
Clopidogrel Tops Aspirin For Atherosclerotic Disease
18 November 1996
Six-Month EPILOG Data Reveal Sustained Benefits
18 November 1996
Nonconsolidated Interims From Fujisawa
11 November 1996
US Biopharma Cos Report 3rd-Qtr Financial Results
11 November 1996
Centocor To Release Six-Month EPILOG Data
4 November 1996
US Quarterly Results Show Improvements
4 November 1996
Centocor License ReoPro To Fujisawa
2 September 1996
Lilly Signs $100 Million Antibiotic Deal With Dura
2 September 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Schering-Plough Chief Gives R&D Update
10 June 1996
Upside Seen For Celltech From Clinical Progress
3 June 1996
US Corporate Quarterly Results Round-Up
13 May 1996
Generics Impact On Eli Lilly But Prozac Strong
22 April 1996
ReoPro Reduces Mortality In CAPTURE Study
15 April 1996
ReoPro In Japan
12 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Cor Plans Integrelin Filing In 1Q96
15 January 1996
Stock Markets Review For 1995
15 January 1996
New York stock comment
8 January 1996
Positive Results For ReoPro In CAPTURE Trial
8 January 1996
Yamanouchi and Protein Design Labs: YM337 trial news
4 December 1995
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
Yamanouchi Launches Omnic In Holland
18 September 1995
Mixed Data From IMPACT-II Trial Of Integrelin
11 September 1995
New York Stock Comment
14 August 1995
Sankyo To Develop Searle's Xemilofiban In Japan
7 August 1995
NEW YORK STOCK COMMENT
29 May 1995
First EU Launch For ReoPro, In UK
15 May 1995
New York Stock Comment
3 April 1995
Celltech Royalties News
20 February 1995
NEW YORK STOCK COMMENT
20 February 1995
NEW YORK STOCK COMMENT
6 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Lilly And Genentech Settle Out Of Court
16 January 1995
US Approval For Centocor's ReoPro
9 January 1995
NEW YORK STOCK COMMENT
26 September 1994
Centocor R&D To Support Profitability in 1995?
22 August 1994
CENTOCOR'S REOPRO NEARS APPROVAL
20 June 1994
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
